Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial
PJ Kertes, IJ Galic, M Greve, G Williams… - JAMA …, 2020 - jamanetwork.com
Importance Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in
Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and
the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at
12 months, to date there are few data on 24-month T&E trials compared with monthly dosing.
Objective To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in
treatment-naive patients with neovascular age-related macular degeneration (nAMD) after …
Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and
the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at
12 months, to date there are few data on 24-month T&E trials compared with monthly dosing.
Objective To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in
treatment-naive patients with neovascular age-related macular degeneration (nAMD) after …